NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, Forecast & News

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) announced its earnings results on Thursday, November, 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.05. View Innovate Biopharmaceuticals' Earnings History.

Innovate Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Innovate Biopharmaceuticals.

1 analysts have issued 12-month price targets for Innovate Biopharmaceuticals' shares. Their forecasts range from $10.00 to $10.00. On average, they expect Innovate Biopharmaceuticals' stock price to reach $10.00 in the next year. This suggests a possible upside of 1,130.6% from the stock's current price. View Analyst Price Targets for Innovate Biopharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innovate Biopharmaceuticals.

Media stories about INNT stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Innovate Biopharmaceuticals.

Innovate Biopharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,830,000 shares, an increase of 8.9% from the December 15th total of 1,680,000 shares. Based on an average daily volume of 431,300 shares, the short-interest ratio is presently 4.2 days. Approximately 8.0% of the shares of the stock are sold short. View Innovate Biopharmaceuticals' Current Options Chain.

Some companies that are related to Innovate Biopharmaceuticals include NeuBase Therapeutics (NBSE), Chimerix (CMRX), OASMIA PHARMACE/ADR (OASM), Eton Pharmaceuticals (ETON), CELYAD SA/ADR (CYAD), Millendo Therapeutics (MLND), Marinus Pharmaceuticals (MRNS), Oncolytics Biotech (ONCY), Scpharmaceuticals (SCPH), CV Sciences (CVSI), Otonomy (OTIC), TFF Pharmaceuticals (TFFP), Aquestive Therapeutics (AQST), Cyclerion Therapeutics (CYCN) and AVEO Pharmaceuticals (AVEO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), Axsome Therapeutics (AXSM), AcelRx Pharmaceuticals (ACRX), Iterum Therapeutics (ITRM), Momo (MOMO), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INNT stock can currently be purchased for approximately $0.81.

Innovate Biopharmaceuticals has a market capitalization of $29.16 million. The company earns $-24,160,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe.View Additional Information About Innovate Biopharmaceuticals.

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/.

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]